Press
September 13, 2021

We’re excited to share our new look!

Press
November 2, 2020

We’re excited to share our new look!

Author

We’re excited to announce our new brand identity to reflect a stronger, more focused, and modern representation of our team and company.

What started as an idea between friends in 2004, has come a long way to today with a fully remote, global team of 135+ (and counting). Larvol empowers healthcare and life sciences experts to improve their strategic decision-making by providing them with custom intelligence reports and SaaS solutions that are accurate, rapid, and expertly curated. Our four core products – Pulse, Conference, Omni, and Veri continue to add significant value to our industry and exemplify our commitment to providing outstanding products to our customers.

We’re excited to announce our new brand identity to reflect a stronger, more focused, and modern representation of our team and company in several ways:

  • first, as our CEO, Bruno Larvol articulates, our brand should communicate our collective vision as a diverse team and who we are, not what we do;
  • second, sharing our internal motto “Semper Tigris” (Latin for ‘always a tiger’) because like tigers, we are fast and on a mission;
  • third, create a more cohesive marketing appearance that reflects our continued evolution as a company as well as into the coming year as we announce additional solutions focused in cancer data in healthcare, and life sciences.

Watch the video where Bruno talks about our brand-

What new changes can you expect?

A new logo demonstrating our focus on simplicity.

A relaunched website with an improved design, fresh look, and branding. Our website has been streamlined to find useful information quickly on products and features and provides an enhanced user experience. We’ve added to our  team section to get to know the team behind it all. Get to know us more here. We’re adding new segmentation for our Blog and Top News sections  to easier find information, articles, and news releases for the latest in healthcare and pharma spaces.

A new motto as mentioned earlier, “Semper Tigris” putting in the spotlight who we are at Larvol. The tiger has featured prominently internally as our “spirit animal” defining our razor-sharp focus, fearless approach to our work, and speed.  

Our social media pages will undergo rebranding as well with added focus on unique content as well as updates and announcements. Don’t miss out on any action, follow us here: Facebook, Twitter, LinkedIn & Instagram.

What remains the same?

Change is the only constant, but what our values including customer focus, innovation, and respect for people remain unchanged. We continue to create robust, scalable, high-quality intelligence tools for the pharmaceutical, life sciences, and healthcare industry and will be expanding our portfolio to include  solutions focused on cancer data research.

We’re incredibly proud of the work we do at Larvol, and are thankful to all our stakeholders (customers, partners, and “Tigers” ) who have accompanied us in our growth. If you wish to know more connect with us at info@larvol.com.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.